白塞病患者可溶性Fas/APO-1水平
Levels of soluble Fas/APO-1 in patients with Behçet's disease.
作者信息
Hamzaoui K, Hamzaoui A, Zakraoui L, Chabbou A
机构信息
Immunohistology Laboratory, Medicine University of Tunis, Tunisia.
出版信息
Mediators Inflamm. 1998;7(2):111-4. doi: 10.1080/09629359891261.
Abstract
The aim of this study was to quantify soluble Fas/APO-1 (sFas/APO-1) protein in the serum of patients with Behcet's disease (BD) in active and inactive stages, compared with patients with systemic lupus erythematosus (SLE) and patients with rheumatoid arthritis (RA). Soluble Fas/APO-1 was quantified using a sandwich enzyme-linked immunosorbent assay. Increased serum sFas/APO-1 levels were observed in active BD, compared with inactive BD, RA patients and SLE patients. Increased serum sFas/APO-1 levels were correlated with the presence of neurologic manifestations or pulmonary involvement in active BD. In conclusion, increased levels of sFas/APO-1 occurred frequently and exclusively in active BD patients. Preliminary evidence suggested that elevated levels of sFas/APO-1 are associated with the clinical stage and clinical manifestations in BD.
摘要
本研究旨在对处于活动期和非活动期的白塞病（BD）患者血清中的可溶性Fas/APO-1（sFas/APO-1）蛋白进行定量，并与系统性红斑狼疮（SLE）患者和类风湿关节炎（RA）患者进行比较。采用夹心酶联免疫吸附测定法对可溶性Fas/APO-1进行定量。与非活动期BD、RA患者和SLE患者相比，活动期BD患者血清sFas/APO-1水平升高。活动期BD患者血清sFas/APO-1水平升高与神经系统表现或肺部受累有关。总之，sFas/APO-1水平升高在活动期BD患者中频繁且仅出现。初步证据表明，BD患者sFas/APO-1水平升高与临床分期及临床表现相关。
相似文献
1
Levels of soluble Fas/APO-1 in patients with Behçet's disease.白塞病患者可溶性Fas/APO-1水平
Mediators Inflamm. 1998;7(2):111-4. doi: 10.1080/09629359891261.
2
Elevated levels of serum soluble Fas are associated with organ and tissue damage in systemic lupus erythematosus among Chinese.在中国人群中，系统性红斑狼疮患者血清可溶性Fas水平升高与器官和组织损伤有关。
Arch Dermatol Res. 2006 Jan;297(7):329-32. doi: 10.1007/s00403-005-0616-2. Epub 2005 Nov 17.
3
Do elevated levels of serum-soluble fas contribute to the persistence of activated lymphocytes in systemic lupus erythematosus?血清可溶性Fas水平升高是否有助于系统性红斑狼疮中活化淋巴细胞的持续存在？
J Autoimmun. 1998 Oct;11(5):457-63. doi: 10.1006/jaut.1998.0233.
4
Relationship of oncogenes (sFas, Bcl-2) and cytokines (IL-10, alfa-TNF) with the activity of systemic lupus erythematosus.癌基因（sFas、Bcl-2）和细胞因子（IL-10、α-TNF）与系统性红斑狼疮活动度的关系。
Anticancer Res. 2001 Jul-Aug;21(4B):3053-9.
5
Serum soluble Fas levels in patients with autoimmune rheumatic diseases.自身免疫性风湿疾病患者的血清可溶性Fas水平
Clin Biochem. 2007 Jan;40(1-2):6-10. doi: 10.1016/j.clinbiochem.2006.09.003. Epub 2006 Sep 16.
6
7
Serum DNase I, soluble Fas/FasL levels and cell surface Fas expression in patients with SLE: a possible explanation for the lack of efficacy of hrDNase I treatment.系统性红斑狼疮患者的血清脱氧核糖核酸酶I、可溶性Fas/FasL水平及细胞表面Fas表达：重组人脱氧核糖核酸酶I治疗无效的一种可能解释
Int Immunol. 2009 Mar;21(3):237-43. doi: 10.1093/intimm/dxn142. Epub 2009 Jan 30.
8
Levels of soluble E-selectin in patients with active Behcet's disease.活动性白塞病患者可溶性E选择素水平
Clin Rheumatol. 2005 Feb;24(1):55-9. doi: 10.1007/s10067-004-0982-8. Epub 2004 Aug 28.
9
Levels of soluble Fas/APO-1/CD95 in systemic lupus erythematosus and juvenile rheumatoid arthritis.系统性红斑狼疮和青少年类风湿性关节炎中可溶性Fas/APO-1/CD95的水平
Arthritis Rheum. 1995 Dec;38(12):1735-7. doi: 10.1002/art.1780381205.
10
Soluble TRAIL concentrations are raised in patients with systemic lupus erythematosus.系统性红斑狼疮患者的可溶性肿瘤坏死因子相关凋亡诱导配体（TRAIL）浓度升高。
Ann Rheum Dis. 2005 Jun;64(6):854-8. doi: 10.1136/ard.2004.029058. Epub 2004 Nov 25.
引用本文的文献
1
Baculoviral inhibitor of apoptosis family of proteins repeat-containing 5 gene methylation status in peripheral blood mononuclear cells and plasma survivin levels in patients with Behçet's disease.白塞病患者外周血单个核细胞中含杆状病毒凋亡抑制蛋白家族重复序列5基因的甲基化状态及血浆生存素水平
Arch Rheumatol. 2021 Jan 14;36(2):185-191. doi: 10.46497/ArchRheumatol.2021.8163. eCollection 2021 Jun.
2
Decreases in the numbers of peripheral blood regulatory T cells, and increases in the levels of memory and activated B cells, in patients with active eosinophilic granulomatosis and polyangiitis.活动性嗜酸性肉芽肿性多血管炎患者外周血调节性 T 细胞数量减少，记忆性和活化 B 细胞水平升高。
J Clin Immunol. 2013 Jul;33(5):965-76. doi: 10.1007/s10875-013-9898-x. Epub 2013 Apr 27.
3
APO-1/Fas gene: Structural and functional characteristics in systemic lupus erythematosus and other autoimmune diseases.APO-1/Fas基因：系统性红斑狼疮及其他自身免疫性疾病中的结构与功能特征
Indian J Hum Genet. 2009 Sep;15(3):98-102. doi: 10.4103/0971-6866.60184.
4
Correlation of CD95 and soluble CD95 expression with acute rejection status of liver transplantation.CD95及可溶性CD95表达与肝移植急性排斥反应状态的相关性
World J Gastroenterol. 2005 Mar 21;11(11):1700-4. doi: 10.3748/wjg.v11.i11.1700.
5
Tc1/Tc2 ratio in the inflammatory process in patients with Behçet's disease.白塞病患者炎症过程中的Tc1/Tc2比值
Mediators Inflamm. 2004 Aug;13(4):247-53. doi: 10.1080/09629350400003167.
6
Expression of Fas antigen and Fas ligand in bronchoalveolar lavage from silicosis patients.矽肺患者支气管肺泡灌洗中Fas抗原和Fas配体的表达。
Mediators Inflamm. 2003 Aug;12(4):209-14. doi: 10.1080/09629350310001599648.
7
Expression of Bcl-2 in inflammatory sites from patients with active Behçet's disease.活动性白塞病患者炎症部位Bcl-2的表达
Mediators Inflamm. 1999;8(2):101-6. doi: 10.1080/09629359990595.
8
Over-expression of the decoy receptor 3 (DcR3) gene in peripheral blood mononuclear cells (PBMC) derived from silicosis patients.矽肺病患者外周血单个核细胞（PBMC）中诱饵受体3（DcR3）基因的过表达。
Clin Exp Immunol. 2000 Feb;119(2):323-7. doi: 10.1046/j.1365-2249.2000.01132.x.
本文引用的文献
1
Levels of soluble Fas/APO-1/CD95 in systemic lupus erythematosus and juvenile rheumatoid arthritis.系统性红斑狼疮和青少年类风湿性关节炎中可溶性Fas/APO-1/CD95的水平
Arthritis Rheum. 1995 Dec;38(12):1735-7. doi: 10.1002/art.1780381205.
2
The role of programmed cell death as an emerging new concept for the pathogenesis of autoimmune diseases.程序性细胞死亡作为自身免疫性疾病发病机制中一个新兴的新概念所起的作用。
Clin Immunol Immunopathol. 1996 Sep;80(3 Pt 2):S2-14. doi: 10.1006/clin.1996.0136.
3
High levels of bcl-2 protein in the T lymphocytes of patients with Behçet's disease.白塞病患者T淋巴细胞中bcl-2蛋白水平较高。
Clin Exp Rheumatol. 1996 Jan-Feb;14(1):106-7.
4
Endothelin-1 expression in serum and bronchoalveolar lavage from patients with active Behçet's disease.活动性白塞病患者血清和支气管肺泡灌洗液中内皮素-1的表达
Br J Rheumatol. 1996 Apr;35(4):357-8. doi: 10.1093/rheumatology/35.4.357.
5
Antibodies to endothelial cells in patients with Behçet's disease.白塞病患者体内针对内皮细胞的抗体。
Clin Immunol Immunopathol. 1993 May;67(2):157-62. doi: 10.1006/clin.1993.1059.
6
CD11/CD18 bearing lymphocytes in cerebrospinal fluid from patients with active Behçet's disease.来自活动期白塞病患者脑脊液中携带CD11/CD18的淋巴细胞。
Clin Exp Rheumatol. 1994 Sep-Oct;12(5):575-6.
7
Apoptosis and autoimmunity.细胞凋亡与自身免疫
J Autoimmun. 1995 Feb;8(1):1-19. doi: 10.1006/jaut.1995.0001.
8
9
Fas ligand mediates activation-induced cell death in human T lymphocytes.Fas配体介导人T淋巴细胞中激活诱导的细胞死亡。
J Exp Med. 1995 Jan 1;181(1):71-7. doi: 10.1084/jem.181.1.71.
10
Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule.可溶形式的Fas分子对Fas介导的细胞凋亡的保护作用。
Science. 1994 Mar 25;263(5154):1759-62. doi: 10.1126/science.7510905.
Zotero 插件